Interview with Alina Culcea, Managing Director, Actavis Romania
We understand that you already took over the reins at Actavis as interim GM in late 2009, before being officially appointed a few months later in 2010. What have been…
Address: Str. Polona, nr. 68 – 72, etaj 3, sector 1, Bucuresti 010505
Tel: +40 21-412.00.17
Web: http://www.egis.ro/
As EGIS Group, we are present with our products in more than 60 countries worldwide and the share of our export revenue in our total sales has been steadily growing, having reached 73% in the 2009/2010 financial year. Our extensive foreign market infrastructure is the guarantee for further growth and international success. Currently we have commercial offices and trading companies in 18 countries. In our strategic markets (Russia, other CIS-countries and Central Eastern Europe) sales is supported by a well-established marketing and distribution network, whereas in our Western and third world markets we work together with local partners.
EGIS Pharmaceuticals PLC is one of the leading pharmaceutical companies in Central Europe. Our most important activities are the production of pharmaceuticals and active pharmaceutical ingredients, pharmaceutical research and development, sales of finished products and active pharmaceutical ingredients.
Out of our three production facilities, two are in Budapest. One of them is seated in our headquarters, in Keresztúri Street, where Active Pharmaceutical Ingredients are made, and the other is in Bökényföldi Street, with our tablet, injection and packaging plants as well as commercial warehouses.
In our third facility, in Körmend, tablets, ointments, suppositories, solutions, syrups and aerosols are made and packaged.
Our production system meets the international GMP principles and the regulations of the Hungarian National Institute of Pharmacy.
Production of Active Pharmaceutical Ingredients
Production of active pharmaceutical ingredients is an important field in the activity of EGIS PLC (and its legal predecessors). As a result of professional experience accumulated through the efforts of the last decades and the continuous modernization of the facilities, competitiveness of the production of active pharmaceutical ingredients has been maintained as it is well proved by successful exports and the good results of the national and international official controls.
At present, in this field of activity approximately 50 different active pharmaceutical ingredients and their intermediates are produced a year. The wide scale of products can be characterized by the gradual renewal and replacement of individual products.
Production of active pharmaceutical ingredients has been able to respond to the challenges of quality assurance and environment protection of the recent past successfully. Thorough grounding and commitment of people working in this strategic field are an important part of the complex professional culture belonging to EGIS.
Pharmaceutical Research and Development
Our research activity is aimed at the development of generic pharmaceutical products offering high marketing potential, the chemical synthesis of putative original drug molecules, and testing of their pharmacological effects. Our research work focuses on drugs effective on cardiovascular diseases, disorders of the central nervous system, the respiratory and digestive systems. At the end of our business year, closed on 30th September 2010, the number of our registrations and marketing authorizations totalled up to 2400.
Sales of Finished Products and Active Pharmaceutical Ingredients
EGIS PLC is ranked third on the basis of the number of packages sold in the Hungarian market, and is placed fifth concerning our sales revenue.
73% of our sales revenue comes from our export activity. We export our finished products first of all to the Eastern regions like Russia, Central- and Eastern-European countries, and the CIS countries. As for the Western countries France and the UK are among our main markets for finished products, while France, the Netherlands, Japan and the United States are considered as the greatest markets for our active ingredients and intermediate export.
We understand that you already took over the reins at Actavis as interim GM in late 2009, before being officially appointed a few months later in 2010. What have been…
A lot of the opportunities and challenges in the pharma and healthcare sector of Romania depend on the overall Romanian business environment in the first place. How would you assess…
If we first take a look at the healthcare system in Romania, it is clear that finding adequate funding has been a key challenge for many years. With 3.6% of…
Ferring is a company with a tremendous history dating back to the 1950s in Sweden. Now present in over 50 countries, the Group has managed to maintain a double digit…
If we take a look back at Boehringer Ingelheim’s dynamic growth path in the Romanian market, we see an evolution from a one-man show in the 1990s to a present…
Records show that the field of homeopathy has a long history in Romania, dating back to the late 1800s. However, the real growth only really took off in the 1990s.…
After an international career of 15 years with Eli Lilly, you are quite new to both the country as well as the company. Looking back at these first 7 months,…
See our Cookie Privacy Policy Here